मूलभूत आँकड़े
| CIK | 1337905 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Intellect Neurosciences, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| February 14, 2018 |
OXISD / OXIS International, Inc. / Honig Barry C Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. |
|
| April 24, 2017 |
EXHIBIT 3.1 22 Grenville Street St Helier Jersey, JE4 8PX www.shire.com 22 March 2017 Elliot Maza Chief Executive Officer Intellect Neurosciences 550 Sylvan Avenue Suite 101 Englewood Cliffs, NJ 07632 Re: Exclusive Licensing Agreement ? Termination and Release of Claims Letter Agreement Dear Elliot: Intellect Neurosciences and ViroPharma n/k/a Shire ViroPharma Incorporated entered into an Exclusiv |
|
| April 24, 2017 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 s1059498k.htm FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2017 Intellect Neurosciences, Inc. (Exact Name Of Registrant As Specified In Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-128226 2 |
|
| February 14, 2017 |
OXISD / OXIS International, Inc. / Honig Barry C Passive Investment SC 13G/A 1 sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. 2 To SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) INTELLECT NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 6 |
|
| September 29, 2016 |
Intellect Neurosciences NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) x Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR For Period Ended: June 30, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition |
|
| May 9, 2016 |
Intellect Neurosciences 10-Q (Quarterly Report) SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934: For the quarterly period ended March 31, 2016 ? TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT OF 1934 Commission file number: 333-128226 INTELLECT NEUROSCIENCES, INC. |
|
| May 9, 2016 |
Intellect Neurosciences EXHIBIT 31.1 EXHIBIT 31.01 OFFICER?S CERTIFICATE PURSUANT TO SECTION 302 I, Elliot Maza, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Intellect Neurosciences, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statemen |
|
| May 9, 2016 |
Intellect Neurosciences EXHIBIT 32.1 EXHIBIT 32.01 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Elliot Maza, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Intellect Neurosciences, Inc. on Form 10-Q for the |
|
| April 28, 2016 |
8-K 1 s1031038k.htm 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2016 (April 14, 2016) Intellect Neurosciences, Inc. (Exact Name Of Registrant As Specified In Its Charter) Delaware (State or Other Jurisdiction of Incorporation) |
|
| April 28, 2016 |
CONVERTIBLE NOTE DUE APRIL ___, 2018 EX-4.1 2 s103103ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SO |
|
| April 28, 2016 |
INTERCREDITOR AND SUBORDINATION AGREEMENT Exhibit 10.2 INTERCREDITOR AND SUBORDINATION AGREEMENT THIS INTERCREDITOR AND SUBORDINATION AGREEMENT, dated as of April , 2016, (this ?Agreement?), is by and among Intellect Neurosciences, Inc., a Delaware corporation (the ?Company?), the parties identified on Schedule A hereto (?Senior Lenders?) and the parties identified on Schedule B hereto (the ?Junior Lenders? and together with Company and S |
|
| April 28, 2016 |
EX-10.1 3 s103103ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April , 2016, between Intellect Neurosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Pu |
|
| February 16, 2016 |
OXISD / OXIS International, Inc. / Honig Barry C - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. 1 To SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) INTELLECT NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 691829402 (CUSIP Number) December 31, |
|
| February 12, 2016 |
ILNS / Intellect Neurosciences, Inc. 10-Q - Quarterly Report - 10-Q 10-Q 1 s10261410q.htm 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934: For the quarterly period ended December 31, 2015 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT OF 1934 Commission file number: 333-128226 INTELLECT NEUROSCIENCES, INC. (Exact name of registrant as spe |
|
| February 12, 2016 |
EXHIBIT 32.01 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Elliot Maza, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Intellect Neurosciences, Inc. on Form 10-Q for the |
|
| February 12, 2016 |
OFFICER’S CERTIFICATE PURSUANT TO SECTION 302 EXHIBIT 31.01 OFFICER’S CERTIFICATE PURSUANT TO SECTION 302 I, Elliot Maza, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Intellect Neurosciences, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statemen |
|
| February 5, 2016 |
SC 13G 1 sc13g0116benjaminintellect.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) INTELLECT NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 691829402 (CUSIP Number) Check the appropriate box to designate the rule pursuant to |
|
| December 8, 2015 |
Exhibit 3.2 EXHIBIT B NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTI |
|
| December 8, 2015 |
Exhibit 3.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of November 30, 2015, between Intellect Neurosciences, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the t |
|
| December 8, 2015 |
8-K 1 s1023308k.htm 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2015 Intellect Neurosciences, Inc. (Exact Name Of Registrant As Specified In Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-128226 20- |
|
| October 26, 2015 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2015 Intellect Neurosciences, Inc. (Exact Name Of Registrant As Specified In Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-128226 20-8329066 (Commission File |
|
| October 26, 2015 |
Exhibit 99.1 Intellect Neurosciences, Inc. Engages Troy Rohn, PhD as Lead Scientific Advisor for TauC3 Antibody Program NEW YORK, October 26, 2015 (GLOBE NEWSWIRE) - Intellect Neurosciences, Inc. (OTC: ILNS) a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of rare neurodegenerative conditions, announced to |
|
| October 21, 2015 |
Intellect Neurosciences, Inc. Issues Letter to Shareholders EX-99.1 2 s102037ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Intellect Neurosciences, Inc. Issues Letter to Shareholders NEW YORK, October 20, 2015 (GLOBE NEWSWIRE) - Intellect Neurosciences, Inc. (OTC:ILNS) a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of rare neurodegenerative conditions, issued the followin |
|
| October 21, 2015 |
8-K 1 s1020378k.htm 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2015 Intellect Neurosciences, Inc. (Exact Name Of Registrant As Specified In Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-128226 20-8 |
|
| September 25, 2015 |
Intellect Neurosciences NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR For Period Ended: June 30, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition |
|
| July 6, 2015 |
EX-3.1 2 s101410ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF DESIGNATIONS, PREFERENCES, AND RIGHTS OF SERIES F CONVERTIBLE PREFERRED STOCK OF INTELLECT NEUROSCIENCES, INC. Intellect Neurosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (“DGCL”), does hereby certify: F |
|
| July 6, 2015 |
EX-3.3 4 s101410ex3-3.htm EXHIBIT 3.3 Exhibit 3.3 INTELLECT NEUROSCIENCES, INC. CERTIFICATE OF DESIGNATIONS, PREFERENCES, AND RIGHTS OF SERIES H CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned, as a person duly authorized to execute this Certificate of Designations, Preferences, and Rights (this “Certificate”) for and on b |
|
| July 6, 2015 |
COMMON STOCK PURCHASE WARRANT INTELLECT NEUROSCIENCES, INC. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 6, 2015 |
EX-3.2 3 s101410ex3-2.htm EXHIBIT 3.2 Exhibit 3.2 INTELLECT NEUROSCIENCES, INC. CERTIFICATE OF DESIGNATIONS, PREFERENCES, AND RIGHTS OF SERIES G CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned, as a person duly authorized to execute this Certificate of Designations, Preferences, and Rights (this “Certificate”) for and on b |
|
| July 6, 2015 |
8-K 1 s1014108k.htm FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2015 Intellect Neurosciences, Inc. (Exact Name Of Registrant As Specified In Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-128226 20- |
|
| July 6, 2015 |
EX-10.1 6 s101410ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 1, 2015, between Intellect Neurosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Pu |
|
| March 10, 2015 |
ILNS / Intellect Neurosciences, Inc. / Honig Barry C - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) INTELLECT NEUROSCIENCES, INC. |
|
| February 10, 2015 |
ILNS / Intellect Neurosciences, Inc. / ALPHA CAPITAL ANSTALT - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) INTELLECT NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) (CUSIP Number) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(c) *The remainder o |
|
| January 6, 2015 |
Entry into a Material Definitive Agreement SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2014 Intellect Neurosciences, Inc. (Exact Name Of Registrant As Specified In Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-128226 20-8329066 (Commission File |
|
| December 19, 2014 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2014 Intellect Neurosciences, Inc. (Exact Name Of Registrant As Specified In Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-128226 20-8329066 (Commission File |
|
| November 14, 2014 |
ILNS / Intellect Neurosciences, Inc. DEF 14A - - DEF 14A DEF 14A 1 s100466def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as Permitted by Rule 1 |
|
| October 30, 2014 |
ILNS / Intellect Neurosciences, Inc. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of |
|
| September 30, 2014 |
ILNS / Intellect Neurosciences, Inc. NT 10-K - - FORM NT 10-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 333-128226 NOTIFICATION OF LATE FILING x Form 10-K ¨ Form 11-K ¨ Form 20-F ¨ Form 10-Q ¨ Form N-SAR For Period Ended: June 30, 2014 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form N-SAR For the Transition Period Ended: Nothing i |
|
| September 29, 2014 |
8-K 1 s1003528k.htm FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2014 Intellect Neurosciences, Inc. (Exact Name Of Registrant As Specified In Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-1282 |
|
| September 29, 2014 |
Intellect Neurosciences, Inc. Issues Letter to Shareholders Intellect Neurosciences, Inc. Issues Letter to Shareholders NEW YORK, September 24, 2014, (GLOBE NEWSWIRE) — Intellect Neurosciences, Inc. (OTCPNK: ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's and other neuro-degenerative diseases today issued the following Letter to Shareholders |
|
| September 23, 2014 |
ILNS / Intellect Neurosciences, Inc. / LONGVIEW FUND LP - SCHEDULE 13G Passive Investment SC 13G 1 v389845sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) INTELLECT NEUROSCIENCES, INC. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) (CUSIP Number) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| August 18, 2014 |
ILNS / Intellect Neurosciences, Inc. 8-A12G - - FORM 8-A12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 INTELLECT NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 20-8329066 (State of incorporation or organization) (I.R.S. Employer Identification No.) 550 Sylvan Ave |
|
| August 15, 2014 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2014 Intellect Neurosciences, Inc. (Exact Name Of Registrant As Specified In Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-128226 20-8329066 (Commission File Num |
|
| August 15, 2014 |
Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF INTELLECT NEUROSCIENCES, INC. Intellect Neurosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: That at a meeting of the Board of Directors of the Corporation resolutions were duly ad |
|
| August 14, 2014 |
8-K 1 v3867658k.htm FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2014 Intellect Neurosciences, Inc. (Exact Name Of Registrant As Specified In Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-128226 |
|
| August 14, 2014 |
Intellect Neurosciences, Inc. Issues Letter to Shareholders Intellect Neurosciences, Inc. Issues Letter to Shareholders NEW YORK, August 13, 2014 (GLOBE NEWSWIRE) - Intellect Neurosciences, Inc. (OTCPNK:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease today issued the following Letter to Shareholders from Elliot Maza, Chairman and CEO. |
|
| July 31, 2014 |
Exhibit 3.1 INTELLECT NEUROSCIENCES, INC. CERTIFICATE OF DESIGNATIONS, PREFERENCES, AND RIGHTS OF SERIES F CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned, as a person duly authorized to execute this Certificate of Designations, Preferences, and Rights (this “Certificate”) for and on behalf of INTELLECT NEUROSCIENCES, INC. |
|
| July 31, 2014 |
Intellect Neurosciences, Inc. Issues Letter to Shareholders EX-99.1 10 v385204ex99-1.htm EXHIBIT 99.1 Intellect Neurosciences, Inc. Issues Letter to Shareholders Exhibit 99.1 NEW YORK, July 30, 2014 (GLOBE NEWSWIRE) — Intellect Neurosciences, Inc. (OTCPNK: ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease today issued the following Lett |
|
| July 31, 2014 |
COMMON STOCK PURCHASE WARRANT INTELLECT NEUROSCIENCES, INC. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 31, 2014 |
Exhibit 3.5 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF DESIGNATIONS, PREFERENCES, AND RIGHTS OF SERIES E CONVERTIBLE PREFERRED STOCK OF INTELLECT NEUROSCIENCES, INC. Intellect Neurosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (“DGCL”), does hereby certify: FIRST: This Certificate of Amendment am |
|
| July 31, 2014 |
EX-10.2 9 v385204ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of July 25, 2014, between Intellect Neurosciences, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreem |
|
| July 31, 2014 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF DESIGNATIONS, PREFERENCES, AND RIGHTS OF SERIES B CONVERTIBLE PREFERRED STOCK OF INTELLECT NEUROSCIENCES, INC. Intellect Neurosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (“DGCL”), does hereby certify: FIRST: This Certificate of Amendment am |
|
| July 31, 2014 |
EX-10.1 8 v385204ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 25, 2014, between Intellect Neurosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “P |
|
| July 31, 2014 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2014 Intellect Neurosciences, Inc. (Exact Name Of Registrant As Specified In Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-128226 20-8329066 (Commission File Num |
|
| July 31, 2014 |
EX-3.3 4 v385204ex3-3.htm EXHIBIT 3.3 Exhibit 3.3 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF DESIGNATIONS, PREFERENCES, AND RIGHTS OF SERIES C CONVERTIBLE PREFERRED STOCK OF INTELLECT NEUROSCIENCES, INC. Intellect Neurosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (“DGCL”), does hereby certify: F |
|
| July 31, 2014 |
Exhibit 3.4 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF DESIGNATIONS, PREFERENCES, AND RIGHTS OF SERIES D CONVERTIBLE PREFERRED STOCK OF INTELLECT NEUROSCIENCES, INC. Intellect Neurosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (“DGCL”), does hereby certify: FIRST: This Certificate of Amendment am |
|
| May 14, 2014 |
NOTIFICATION OF LATE FILING SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 333-128226 NOTIFICATION OF LATE FILING ¨ Form 10-K ¨ Form 11-K ¨ Form 20-F x Form 10-Q ¨ Form N-SAR For Period Ended: March 31, 2014 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form N-SAR For the Trans |
|
| February 14, 2014 |
Intellect Neurosciences FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON , D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2013 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-128226 INTE |
|
| November 12, 2013 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 333-128226 NOTIFICATION OF LATE FILING ¨ Form 10-K ¨ Form 11-K ¨ Form 20-F x Form 10-Q ¨ Form N-SAR For Period Ended: September 30, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form N-SAR For the Transition Period Ended: Noth |
|
| September 25, 2013 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 333-128226 NOTIFICATION OF LATE FILING x Form 10-K ¨ Form 11-K ¨ Form 20-F o Form 10-Q ¨ Form N-SAR For Period Ended: June 30, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form N-SAR For the Transition Period Ended: Nothing i |
|
| August 12, 2013 |
Financial Statements and Exhibits, Other Events - FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2013 Intellect Neurosciences, Inc. (Exact Name Of Registrant As Specified In Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-128226 20-2777006 (Commission File Num |
|
| August 12, 2013 |
Intellect Neurosciences Retains Chain Pharmaceuticals LLC EX-99.1 2 v352606ex99-1.htm EXHIBIT 99.1 Intellect Neurosciences Retains Chain Pharmaceuticals LLC NEW YORK, July 30, 2013 – Intellect Neurosciences, Inc. (OTCBB: ILNS) announced today it has retained Chain Pharmaceuticals LLC as a consultant to assist the company in managing its patent estate and external collaborations and pursuing strategic alternatives for the company, which may include partne |
|
| May 14, 2013 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 333-128226 NOTIFICATION OF LATE FILING ¨ Form 10-K ¨ Form 11-K ¨ Form 20-F x Form 10-Q ¨ Form N-SAR For Period Ended: March 31, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form N-SAR For the Transition Period Ended: Nothing |
|
| May 10, 2013 |
EX-99.1 2 v344594ex99-1.htm EXHIBIT 99.1 |
|
| May 10, 2013 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2013 Intellect Neurosciences, Inc. (Exact Name Of Registrant As Specified In Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-128226 20-2777006 (Commission File Numbe |
|
| January 18, 2013 |
Unregistered Sales of Equity Securities - CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2013 Intellect Neurosciences, Inc. (Exact Name Of Registrant As Specified In Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-128226 20-8329066 (Commission File N |
|
| November 14, 2012 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 333-128226 NOTIFICATION OF LATE FILING ¨ Form 10-K ¨ Form 11-K ¨ Form 20-F x Form 10-Q ¨ Form N-SAR For Period Ended: September 30, 2012 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form N-SAR For the Transition Period Ended: Noth |
|
| October 12, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2012 Intellect Neurosciences, Inc. (Exact Name Of Registrant As Specified In Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-128226 20-8329066 (Co |
|
| September 25, 2012 |
NT 10-K 1 v324400nt10k.htm FORM NT 10-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 333-128226 NOTIFICATION OF LATE FILING x Form 10-K ¨ Form 11-K ¨ Form 20-F o Form 10-Q ¨ Form N-SAR For Period Ended: June 30, 2012 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form N-SAR Fo |
